Literature DB >> 27756975

Prescribing psychotropic drugs to adults with an intellectual disability.

Julian N Trollor1, Carmela Salomon1, Catherine Franklin2.   

Abstract

Mental illness is common in people with intellectual disability. They may also have physical health problems which can affect their mental state. Difficulties in communication can contribute to mental health problems being overlooked. These may present with changes in behaviour. Psychological management is usually preferable to prescribing psychotropic drugs. Behavioural approaches are the most appropriate way to manage challenging behaviour. If a drug is considered, prescribers should complete a thorough diagnostic assessment, exclude physical and environmental contributions to symptoms, and consider medical comorbidities before prescribing. Where possible avoid psychotropics with the highest cardiometabolic burden. Prescribe the minimum effective dose and treatment length, and regularly monitor drug efficacy and adverse effects. There is insufficient evidence to support the use of psychotropics for challenging behaviour. They should be avoided unless the behaviour is severe and non-responsive to other treatments.

Entities:  

Keywords:  antipsychotic drug therapy; genetic syndrome; intellectual disability

Year:  2016        PMID: 27756975      PMCID: PMC4993707          DOI: 10.18773/austprescr.2016.048

Source DB:  PubMed          Journal:  Aust Prescr        ISSN: 0312-8008


  10 in total

Review 1.  Antipsychotic medication for challenging behaviour in people with learning disability.

Authors:  J Brylewski; L Duggan
Journal:  Cochrane Database Syst Rev       Date:  2004

2.  People with intellectual disabilities.

Authors:  Sally-Ann Cooper; Craig Melville; Jillian Morrison
Journal:  BMJ       Date:  2004-08-21

3.  Pharmacological management of challenging behavior of individuals with intellectual disability.

Authors:  Jane A McGillivray; Marita P McCabe
Journal:  Res Dev Disabil       Date:  2004 Nov-Dec

Review 4.  Aripiprazole for autism spectrum disorders (ASD).

Authors:  Heidi Ching; Tamara Pringsheim
Journal:  Cochrane Database Syst Rev       Date:  2012-05-16

5.  International guide to prescribing psychotropic medication for the management of problem behaviours in adults with intellectual disabilities.

Authors:  Shoumitro Deb; Henry Kwok; Marco Bertelli; Luis Salvador-Carulla; Elspeth Bradley; Jennifer Torr; Jarret Barnhill
Journal:  World Psychiatry       Date:  2009-10       Impact factor: 49.548

6.  Characteristics and the trajectory of psychotropic medication use in general and antipsychotics in particular among adults with an intellectual disability who exhibit aggressive behaviour.

Authors:  S Deb; G Unwin; T Deb
Journal:  J Intellect Disabil Res       Date:  2014-01-22

7.  Psychopathology in children and adolescents with autism compared to young people with intellectual disability.

Authors:  Avril V Brereton; Bruce J Tonge; Stewart L Einfeld
Journal:  J Autism Dev Disord       Date:  2006-10

8.  Risperidone, haloperidol, and placebo in the treatment of aggressive challenging behaviour in patients with intellectual disability: a randomised controlled trial.

Authors:  Peter Tyrer; Patricia C Oliver-Africano; Zed Ahmed; Nick Bouras; Sherva Cooray; Shoumitro Deb; Declan Murphy; Monica Hare; Michael Meade; Ben Reece; Kofi Kramo; Sabyasachi Bhaumik; David Harley; Adrienne Regan; David Thomas; Bharti Rao; Bernard North; Joseph Eliahoo; Shamshad Karatela; Anju Soni; Mike Crawford
Journal:  Lancet       Date:  2008-01-05       Impact factor: 79.321

9.  Drug treatments in people with intellectual disability and challenging behaviour.

Authors:  Peter Tyrer; Sally-Ann Cooper; Angela Hassiotis
Journal:  BMJ       Date:  2014-07-04

Review 10.  Risperidone for autism spectrum disorder.

Authors:  O S Jesner; M Aref-Adib; E Coren
Journal:  Cochrane Database Syst Rev       Date:  2007-01-24
  10 in total
  6 in total

1.  Case study: organizing outpatient pharmacological treatment of bipolar disorder in autism, intellectual disability and Phelan-McDermid syndrome (22q13.3 deletion syndrome).

Authors:  Anne Langseth Rysstad; Arvid Nikolai Kildahl; Jon Olav Skavhaug; Monica Stolen Dønnum; Sissel Berge Helverschou
Journal:  Int J Dev Disabil       Date:  2020-06-09

2.  Asthma in intellectual disability: are we managing our patients appropriately?

Authors:  Sharon Davis
Journal:  Breathe (Sheff)       Date:  2016-12

3.  Psychotropic medication and psychotherapeutic treatment of adults with intellectual disabilities (PROMPT-ID): a cross-sectional, epidemiological study in Saxony, Germany.

Authors:  Andrea Koch; Julia Dobrindt; Matthias Schützwohl
Journal:  BMJ Open       Date:  2018-12-19       Impact factor: 2.692

4.  Pharmacotherapy for mood and anxiety disorders in older people with intellectual disability in comparison with the general population.

Authors:  Anna Axmon; Nadia El Mrayyan; Jonas Eberhard; Gerd Ahlström
Journal:  BMC Psychiatry       Date:  2019-08-01       Impact factor: 3.630

5.  Appropriateness of psychotropic medication use in a cohort of adolescents with intellectual disability in Queensland, Australia.

Authors:  Menghuan Song; Robert S Ware; Tan N Doan; Lyn McPherson; Julian N Trollor; David Harley
Journal:  BJPsych Open       Date:  2020-11-17

6.  Management of psychotropic medications in adults with intellectual disability: a scoping review protocol.

Authors:  Ashley Costello; Cian Hehir; Drona Sharma; Eithne Hudson; Owen Doody; Dervla Kelly
Journal:  HRB Open Res       Date:  2022-01-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.